Natera (NTRA) Maps Signatera Growth, Is It Still 30% Below Fair Value?

Simply Wall St · 16h ago

Natera (NTRA) has moved into focus after its CFO outlined a multi year revenue plan centered on the Signatera cancer testing franchise, tying that roadmap to recent clinical data and upcoming study milestones.

Recent trading has been choppy for Natera, with the share price down 26.68% over the past 30 days and 11.26% over 90 days. However, the stock is still showing a 26.06% year-to-date share price return and a 35.02% total shareholder return over one year, which points to longer-term momentum that has cooled in the short run as investors digest fresh Signatera data, raised 2026 revenue guidance, new oncology collaborations, and a CEO transition.

Scan beyond Natera and identify additional precision medicine players investors are watching by running the curated 36 healthcare AI stocks that aligns with this oncology and diagnostics theme.

Natera’s recent pullback sits at the crossroads of brisk Signatera progress and a cooler mood toward high growth diagnostics, so the next step is to test whether the current share price still fits the story.

Most Popular Narrative: 29.6% Undervalued

Natera’s last close of $288.48 sits well below the fair value of $410.02 implied by the analyst consensus Narrative on Simply Wall St, which applies a 7.5% discount rate and folds in long range revenue and earnings forecasts.

Execution against a large MRD testing opportunity, where Signatera is generating just over US$1b of revenue on low single digit penetration and management frames a US$20b to US$40b annual addressable market and a long term ASP goal of about US$2,000, leaves scope for higher revenue and operating leverage if volumes and pricing move toward those targets.

See why 21 investors see Natera as 30% undervalued.

Result: Fair Value of $410.02 (UNDERVALUED)

Still, the narrative can crack if Natera’s ongoing net losses deepen or if early cancer detection programs absorb heavy R&D without producing timely revenue.

Find out about the key risks to this Natera narrative.

Another View: Natera Through The P/S Lens

The story looks different once price is compared to sales. Natera trades on a P/S of 14.4x, which is richer than the US Biotechs average of 9.8x, the peer average of 4.8x, and its own fair ratio of 10.9x. That gap suggests investors are already paying up, so how much margin of safety is really left?

To pressure test this richer P/S picture against the earlier fair value narrative, use the See what the numbers say about this price — find out in our valuation breakdown..

NasdaqGS:NTRA P/S Ratio as at Nov 2026
NasdaqGS:NTRA P/S Ratio as at Nov 2026

Next Steps

Mixed signals around Natera’s valuation and business traction can feel confusing. Move quickly, review the underlying numbers, and weigh both sides of the story using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Natera?

Do not stop at one stock. Use the same disciplined lens across other opportunities and let the data do the heavy lifting for your next move.